Inflammatory Bowel Disease (IBD)


TARGET-IBD continues to collect valuable real-world data which enhances our understanding of the natural history of inflammatory bowel disease and the impact of different treatment paradigms on patient populations over time. The outcomes from real-world evidence can help doctors as they work to provide treatments to individual patients in real-life settings. This is particularly important given the ongoing innovation in the treatment of IBD. Millie Long, MD, MPH

According to the Centers for Disease Control and Prevention, it is estimated that a total of 1.3% or 3 million adults in the United States were diagnosed with Inflammatory Bowel Disease (IBD) in 2015 alone. As millions continue to be diagnosed each year, it has become evident that there is a need for real-world, longitudinal data to better understand and evaluate the disease.

TARGET-IBD is a 5-year longitudinal observational study of adult and pediatric patients (age 2 and above) who are undergoing therapy for IBD within academic and community real-world centers. The study aims to collect data that is critical in establishing real-world evidence findings for the IBD disease, given that robust pipelines of new chemical entities and bio-similar entrants continue to have profound effects on patient management.

The IBD platform aggregates various sets of consented, real-world patient data from medical records, patient-reported outcome measures, and clinically linked biospecimens. Partners can query the longitudinal dataset to support their drug development programs and RWE initiatives.

Study Goals:

  • Expand enrollment of the TARGET-IBD cohort with rapid acquisition of detailed clinical data from academic and community practice settings

  • Explore the safety and effectiveness of the entire spectrum of current and future therapies, including the occurrence of switching to bio-similars, that are utilized in usual clinical practice across diverse populations


August 2017


Enrollment Goal:

Up to 15,000

TARGET-IBD Steering Committee

Bruce Sands, MD (Co-Chair)
Dr. Burrill B. Crohn Professor of Medicine, New York, NY

Millie D. Long, MD, MPH (Co-Chair)
Associate Professor of Medicine, Chapel Hill, NC

David Rubin, MD (Co-Chair)
Joseph B. Kirsner Professor of Medicine, Chicago, IL

Marla Dubinsky, MD
Chief of the Division of Pediatric Gastroenterology and Professor of Medicine, New York, NY

Miguel Regueiro, MD
Professor and Chairman of Gastroenterology and Hepatology, Cleveland, OH 

Interested in launching a new disease registry?

Target RWE has developed a turnkey solution to rapidly activate disease agnostic registries to support partners.